Newport News, VA - Allan Murphy, M.D. and Riverside Regional Medical Center announced today, its participation in the ALERTS Pivotal US trial for the AngelMed Guardian implantable cardiac monitor and alert system. The system is designed to reduce the time it takes patients to get to the emergency room during an impending heart attack.
The AngelMed Guardian system is designed to track significant changes in the heart's electrical signal and then alert patients to seek medical attention. The objective of the ALERTS Pivotal Study is to provide an assessment of the safety and effectiveness of the AngelMed Guardian System.
“If the Guardian system proves to be effective in early detection and warning of potentially life-threatening heart conditions, it might help save lives. Also, when no warning signal is received, it could be reassuring to patients that their symptoms are not coming from their heart and prevent unnecessary hospitalizations and testing,” said Dr. Allan Murphy, Principal Investigator for Riverside Regional Medical Center. “We are excited to participate in this important clinical trial.” Dr. Murphy continued.
According to the American Heart Association, one of every five deaths in the US is attributable to coronary heart disease. Further, 50% of heart-attack fatalities occur within one hour of symptom onset and occur before the patient even reaches the hospital.
"Experimental and clinical studies have shown that most of the damage to the heart occurs during the first two hours after coronary occlusion," says AngelMed's Chief Operating Officer Jonathan Harwood. "We've designed the device to warn patients of this and other cardiac events hours--perhaps days--before they occur."
The AngelMed Guardian System is comprised of an internal implantable device about the size of a standard pacemaker with a lead into the heart, an external telemetry device, and a programmer that aids physicians in evaluating heart signals.
"When someone has a heart attack, it is typically the result of a blood clot closing one of the three major coronary arteries. When this happens, there is a shift in the ST segment of the heart signal caused by the electrical difference between the portion of the heart muscle fed by the closed artery and the rest of the heart that is still receiving oxygen," adds AngelMed's CEO, David Fischell, Ph.D. "The ALERTS trial is designed to test the Guardian's ability to detect this electrical shift in a clinical setting and then provide an early warning to patients that could potentially save their lives."
Riverside Regional Medical Center is among the first medical facilities to participate in the AngelMed Guardian system trial. To participate in the ALERTS study, patients must meet various inclusion criteria. For more information on the AngelMed Guardian system or the ALERTS study protocol, contact Virginia Oehmann, RN, MSN at 757-594-4508 or firstname.lastname@example.org.
Published: June 12, 2009